ArticleClinical cancer research : an official journal of the American Association for Cancer Research2012

The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial.

Jason J Luke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.